Building the Future of Trial Design in PAH on Solid Ground

[摘要] During the last 2 decades, significant improvements have been achieved in the management of pulmonary arterial hypertension (PAH). From the very first successful trial addressing the role of IV epoprostenol¹ in PAH, patients not only present better hemodynamics and functional capacity with treatment but also better quality of life and survival.² Although the development of new drugs had a significant impact in such improvements, the improvements cannot be solely attributed to this factor. New treatment strategies also represented a paradigm shift in PAH; these new strategies varied from the use of monotherapy, through the use of a second add-on therapy,³ until, more recently, upfront oral combination therapy.

[学科分类] 呼吸医学